Repare Therapeutics Inc. (NASDAQ:RPTX) Forecasted to Earn FY2024 Earnings of ($1.94) Per Share

Repare Therapeutics Inc. (NASDAQ:RPTX) – Stock analysts at Bloom Burton upped their FY2024 earnings per share (EPS) estimates for Repare Therapeutics in a research report issued on Thursday, September 12th. Bloom Burton analyst D. Martin now forecasts that the company will earn ($1.94) per share for the year, up from their previous forecast of ($2.92). The consensus estimate for Repare Therapeutics’ current full-year earnings is ($2.31) per share.

Several other equities research analysts have also recently weighed in on the company. Lifesci Capital upgraded Repare Therapeutics to a “strong-buy” rating in a research note on Monday, July 29th. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Repare Therapeutics in a report on Wednesday, September 4th. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Repare Therapeutics has a consensus rating of “Buy” and a consensus price target of $17.33.

Repare Therapeutics Price Performance

NASDAQ RPTX opened at $3.32 on Monday. The business has a fifty day moving average price of $3.27 and a two-hundred day moving average price of $3.72. Repare Therapeutics has a fifty-two week low of $2.71 and a fifty-two week high of $13.85. The stock has a market capitalization of $140.93 million, a PE ratio of -3.02 and a beta of 0.71.

Repare Therapeutics (NASDAQ:RPTX) last released its earnings results on Tuesday, August 6th. The company reported ($0.82) earnings per share for the quarter, topping the consensus estimate of ($0.85) by $0.03. Repare Therapeutics had a negative return on equity of 31.11% and a negative net margin of 99.76%. The firm had revenue of $1.07 million during the quarter, compared to analysts’ expectations of $4.02 million.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. XTX Topco Ltd acquired a new position in shares of Repare Therapeutics during the second quarter worth $110,000. Jump Financial LLC acquired a new stake in Repare Therapeutics in the fourth quarter valued at $289,000. Opaleye Management Inc. acquired a new stake in Repare Therapeutics in the first quarter valued at $318,000. Marshall Wace LLP acquired a new stake in Repare Therapeutics in the second quarter valued at $273,000. Finally, Bank of Montreal Can increased its holdings in Repare Therapeutics by 5.4% in the second quarter. Bank of Montreal Can now owns 110,935 shares of the company’s stock valued at $366,000 after purchasing an additional 5,673 shares during the period. 85.09% of the stock is currently owned by institutional investors and hedge funds.

About Repare Therapeutics

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.